Actinium Pharmaceuticals, Inc. (ATNM) Stock Price & Analysis

Actinium Pharmaceuticals, Inc. (ATNM) rose 19.42% to USD 1.23 as of September 9, 2026 at 06:42 UTC, according to Nexqual real-time market data.

ATNM last closed at USD 1.03; the session ranged USD 1.06–1.25 on volume of 569,098 shares. Market capitalization is $38.59M, with a 52-week range of USD 0.74–1.74 (ASE). Source: Nexqual, September 9, 2026 at 06:42 UTC.

Key Statistics (as of September 9, 2026 at 06:42 UTC)

Technical Analysis (ATNM)

Nexqual's technical model rates ATNM "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of September 9, 2026 at 06:42 UTC.

Analyst Ratings (ATNM)

Wall Street analysts rate ATNM "None" based on 4 analysts, with a mean price target of USD 3.5 (range USD 2–5), per Nexqual as of September 9, 2026 at 06:42 UTC.

Earnings (ATNM)

Recent Earnings History

Source: Nexqual, September 9, 2026 at 06:42 UTC.

Financials & Fundamentals (ATNM)

Source: Nexqual, September 9, 2026 at 06:42 UTC.

Financial Health Score (ATNM)

Nexqual rates Actinium Pharmaceuticals, Inc.'s overall financial health "Solid" across five dimensions, as of September 9, 2026 at 06:42 UTC.

Ownership (ATNM)

Source: Nexqual, September 9, 2026 at 06:42 UTC.

Leadership (ATNM)

Actinium Pharmaceuticals, Inc. is led by Sandesh C. Seth M.B.A., M.S. (age 61), CEO, Principal Financial Officer & Chairman, per Nexqual as of September 9, 2026 at 06:42 UTC.

Major Backers & Investors (ATNM)

Notable institutional backers of Actinium Pharmaceuticals, Inc. include Compass Financial Management LLC, Millennium Management, Acadian Asset Management. LLC, according to Nexqual as of September 9, 2026 at 06:42 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, September 9, 2026 at 06:42 UTC.

From Actinium Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• This vertical integration provides us with significant strategic flexibility and insulates us from supply chain disruptions that have historically challenged radiopharmaceutical development.   Strong Intellectual Property Position   We have built an intellectual property portfolio comprising approximately 250 issued patents and pending patent applications, including critical composition of matter patents, method of use patents, and proprietary Ac-225 production technology.
• We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position.   Our intellectual property portfolio comprises approximately 250 patents and patent applications across multiple jurisdictions.
• In addition, we will opportunistically seek partnerships to manufacture Ac-225 utilizing our patented cyclotron production technology.   6     Continue Platform Innovation and Pipeline Expansion   We are committed to continued innovation in radiopharmaceutical discovery and development.
• We must also comply with regulations governing the transportation of radioactive materials, including such regulation by the US Department of Transportation.   The FDA has issued guidance documents specific to radiopharmaceuticals that address topics including dosimetry assessments, clinical trial design, and manufacturing controls.

Partnerships

• This positions Actimab-A to potentially expand the $40+ billion PD-1 inhibitor market.   De-Risked Late-Stage Hematology Franchise with Near-Term Partnership Potential   Our hematology programs are supported by extensive clinical validation and represent potential near-term value creation opportunities.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 06:42 UTC. This page is informational and not investment advice.